Literature DB >> 28365334

Can Locoregionally Recurrent Breast Cancer Be Cured?

Arati Rani Chand1, M Firdos Ziauddin2, Shou-Ching Tang3.   

Abstract

Locoregional recurrence (LRR) of breast cancer can occur after multidisciplinary treatment of a primary breast cancer. With modern multidisciplinary breast cancer treatment, the incidence of isolated LRR is decreasing. Improvements in systemic therapy are driving the decrease in LRR. LRR does still occur, however. LRR reflects biology of the cancer, as does systemic recurrence. LRR of breast cancer is frequently associated with systemic disease recurrence and poor prognosis. Given this associated poor prognosis, historically, it has been unclear whether patients with LRR would benefit from aggressive therapy with curative intent. Findings in retrospective studies suggest that prognosis for patients with LRR is not universally poor, and some patients may benefit from aggressive locoregional and systemic therapy. The challenge remains to assess prognosis and appropriately treat patients with locoregional breast cancer recurrence.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Locoregional recurrence; Prognosis; Radiation; Surgery; Systemic therapy

Mesh:

Year:  2017        PMID: 28365334     DOI: 10.1016/j.clbc.2017.02.007

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  2 in total

1.  Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients.

Authors:  Qingtao Ni; Ines Stevic; Chi Pan; Volkmar Müller; Leticia Oliveira-Ferrer; Klaus Pantel; Heidi Schwarzenbach
Journal:  Sci Rep       Date:  2018-08-28       Impact factor: 4.379

2.  DEAD-box RNA Helicase 39 Promotes Invasiveness and Chemoresistance of ER-positive Breast Cancer.

Authors:  Xiudi Wang; Peipei Li; Chenying Wang; Dagui Zhang; Linghui Zeng; Xiyong Liu; Jiajin Lin
Journal:  J Cancer       Date:  2020-01-20       Impact factor: 4.207

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.